journal article·2017-03-08

Facial Layer-by-Layer Engineering of Upconversion Nanoparticles for Gene Delivery: Near-Infrared-Initiated Fluorescence Resonance Energy Transfer Tracking and Overcoming Drug Resistance in Ovarian Cancer

Min Lin, Yan Gao, Thomas J. Diefenbach, Jacson K. Shen, Francis J. Hornicek, Yong Il Park, Feng Xu, Tian Jian Lu, Mansoor Amiji, Zhenfeng Duan

Publisher page

Abstract

Development of multidrug resistance (MDR) contributes to the majority of treatment failures in clinical chemotherapy. We report facial layer-by-layer engineered upconversion nanoparticles (UCNPs) for near-infrared (NIR)-initiated tracking and delivery of small interfering RNA (siRNA) to enhance chemotherapy efficacy by silencing the MDR1 gene and resensitizing resistant ovarian cancer cells to drug. Layer-by-layer engineered UCNPs were loaded with MDR1 gene-silencing siRNA (MDR1-siRNA) by electrostatic interaction. The delivery vehicle enhances MDR1-siRNA cellular uptake, protects MDR1-siRNA from nuclease degradation, and promotes endosomal escape for silencing the MDR gene. The intrinsic photon upconversion of UCNPs provides an unprecedented opportunity for monitoring intracellular attachment and release of MDR1-siRNA by NIR-initiated fluorescence resonance energy transfer occurs between donor UCNPs and acceptor fluorescence dye-labeled MDR1-siRNA. Enhanced chemotherapeutic efficacy in vitro was demonstrated by cell viability assay. The developed delivery vehicle holds great potential in delivery and imaging-guided tracking of therapeutic gene targets for effective treatment of drug-resistant cancers.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Ragon Institute of MGH, Massachusetts Institute of Technology (MIT) and Harvard University, Boston, Massachusetts 02139, United States

School of Chemical Engineering, Chonnam National University, Gwangju 61186, Republic of Korea

Department of Pharmaceutical Sciences, School of Pharmacy, Northeastern University, Boston, Massachusetts 02115, United States

Funding

National Cancer Institute · Ministry of Education of the People's Republic of China · Sarcoma Foundation of America · National Natural Science Foundation of China · Gategno and Wechsler Funds

References (52)

Show source-provided references
1. 10.3322/caac.2120810.3322/caac.21208 ↗
2. 10.3322/caac.2125410.3322/caac.21254 ↗
3. 10.1038/nrclinonc.2013.510.1038/nrclinonc.2013.5 ↗
4. 10.1038/nrc314410.1038/nrc3144 ↗
5. 10.1158/1078-0432.CCR-04-068310.1158/1078-0432.CCR-04-0683 ↗
6. 10.1038/nrc359910.1038/nrc3599 ↗
7. 10.1021/ja409886210.1021/ja4098862 ↗
8. 10.1186/1471-2407-14-68110.1186/1471-2407-14-681 ↗
9. 10.1016/j.biomaterials.2014.09.01710.1016/j.biomaterials.2014.09.017 ↗
10. 10.1038/3588810.1038/35888 ↗
11. 10.1016/j.jconrel.2014.11.01910.1016/j.jconrel.2014.11.019 ↗
12. 10.1002/smll.20100138910.1002/smll.201001389 ↗
13. 10.1039/c3cs60309a10.1039/c3cs60309a ↗
14. 10.1146/annurev-bioeng-071813-10511910.1146/annurev-bioeng-071813-105119 ↗
15. 10.1016/j.biomaterials.2014.06.02410.1016/j.biomaterials.2014.06.024 ↗
16. 10.1021/nl304287a10.1021/nl304287a ↗
17. 10.1021/nn302468810.1021/nn3024688 ↗
18. 10.1038/srep0850910.1038/srep08509 ↗
19. 10.1021/nn500777n10.1021/nn500777n ↗
20. 10.1021/cr400532z10.1021/cr400532z ↗
21. 10.1021/ar500217w10.1021/ar500217w ↗
22. 10.1016/j.ccr.2014.01.00410.1016/j.ccr.2014.01.004 ↗
23. 10.1016/j.biotechadv.2012.04.00910.1016/j.biotechadv.2012.04.009 ↗
24. 10.1038/nprot.2013.11410.1038/nprot.2013.114 ↗
25. 10.1002/adfm.20150158210.1002/adfm.201501582 ↗
26. 10.1002/adfm.20150367210.1002/adfm.201503672 ↗
27. 10.1039/C5RA13184G10.1039/C5RA13184G ↗
28. 10.1021/acsnano.5b0201410.1021/acsnano.5b02014 ↗
29. 10.1021/acsnano.5b0064110.1021/acsnano.5b00641 ↗
30. 10.1021/am403554x10.1021/am403554x ↗
31. 10.1021/la102872v10.1021/la102872v ↗
32. 10.1021/la904011q10.1021/la904011q ↗
33. 10.1039/C4NR02495H10.1039/C4NR02495H ↗
34. 10.1039/C2NR32835F10.1039/C2NR32835F ↗
35. 10.1088/0957-4484/20/15/15510110.1088/0957-4484/20/15/155101 ↗
36. 10.1073/pnas.111455110910.1073/pnas.1114551109 ↗
37. 10.1016/j.cis.2015.10.00310.1016/j.cis.2015.10.003 ↗
38. Duan Z. · Clin. Cancer Res. · 1999 · 5 · 3445
39. Duan Z. · Mol. Cancer. Ther. · 2004 · 3 · 83310.1158/1535-7163.833.3.7 ↗
40. 10.18632/oncotarget.322010.18632/oncotarget.3220 ↗
41. 10.1039/C4NR06944G10.1039/C4NR06944G ↗
42. 10.1038/srep0777910.1038/srep07779 ↗
43. 10.1002/smll.20100131410.1002/smll.201001314 ↗
44. 10.1002/smll.20090151310.1002/smll.200901513 ↗
45. 10.1016/j.aca.2013.04.02510.1016/j.aca.2013.04.025 ↗
46. 10.1016/j.cap.2011.03.07310.1016/j.cap.2011.03.073 ↗
47. 10.1016/S0378-5173(02)00548-310.1016/S0378-5173(02)00548-3 ↗
48. 10.1038/nature1433710.1038/nature14337 ↗
49. 10.1039/C3CS60184F10.1039/C3CS60184F ↗
50. 10.1021/nn301383810.1021/nn3013838 ↗
51. 10.1039/C5RA00397K10.1039/C5RA00397K ↗
52. 10.1021/nl071729+10.1021/nl071729+ ↗